The short answer
Some ashwagandha preparations can cause drowsiness, but added sedation with ropinirole has not been established. Review the exact product with your clinician before adding it, particularly if you already have daytime sleepiness.
What this answer covers
Withania somnifera products; the root-only trial does not establish equivalent effects for leaf extracts or mixed products.
- Supplement or preparation
- Withania somnifera
- Medication ingredient
- ropinirole
What the safety guidance says
NCCIH notes that some ashwagandha preparations cause drowsiness and may interact with sedatives. Because ropinirole already carries a sleepiness warning, your existing alertness and other medicines matter.
Why the sleep trial does not answer this question
A ten-week root-extract trial reported some improved sleep outcomes and no adverse events. It excluded regular medication users and people with restless legs syndrome, so it does not establish safety with ropinirole.
Root extract is not every ashwagandha product
The trial used a specific root-only extract. Its results cannot be applied automatically to leaf extracts or products with several ingredients. Review the formulation and planned duration; no evidence establishes a dose interval that prevents impairment.
When daytime sleepiness needs attention
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
Intrinsic drowsiness guidance supports a conditional precaution; the controlled root-extract trial does not test this pair.
- Exact scope
- Withania somnifera products; the root-only trial does not establish equivalent effects for leaf extracts or mixed products. with Oral immediate-release ropinirole, with hydrochloride salt expressed as equivalent free base in label section 11.
- Medication form and route
- oral
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- The trial excluded regular medication users and restless legs syndrome, limiting relevance to ropinirole-treated patients.
Factors that may matter: baseline alertness; exact preparation; other medicines; treatment indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
No direct study of these six supplement combinations. Immediate-release tablet context does not establish release-form or dose interchangeability.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Some preparations can cause drowsiness; possible interaction with sedatives. Products and studied preparations vary.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
No direct ropinirole study; short-term safety observations do not establish long-term safety.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults enrolled with insomnia and anxiety.
Some sleep outcomes improved; no adverse events were reported. Morning alertness did not differ significantly between groups at ten weeks.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Regular medication users and people with restless legs syndrome or other sleep disorders were excluded. Exploratory study; internal reporting inconsistencies in analysis counts. Cannot extend to ropinirole-treated patients or leaf preparations.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Targeted sources inspected and all current available claims adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: 11d9abd911df81de
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.